<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><description>肿瘤学临床研究及制药企业研发评述</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 18 Apr 2021 15:22:13 +0800</pubDate><image><url>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</url><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>“唱响璀璨友生”2021世界血友病日主题活动顺利举办</title><link>https://mp.weixin.qq.com/s/XrSasca53GM5WQH48yhyfA</link><description></description><content:encoded><![CDATA[“唱响璀璨友生”2021世界血友病日主题活动顺利举办]]></content:encoded><pubDate>Sun, 18 Apr 2021 15:02:18 +0800</pubDate></item><item><title>看新闻 涨知识 I FDA批准nivloluamb联合化疗治疗胃癌一线适应症</title><link>https://mp.weixin.qq.com/s/gQ6fYlGsvgSLcNMrlgDj3g</link><description></description><content:encoded><![CDATA[看新闻 涨知识 I FDA批准nivloluamb联合化疗治疗胃癌一线适应症]]></content:encoded><pubDate>Sat, 17 Apr 2021 09:37:32 +0800</pubDate></item><item><title>武田注射用维布妥昔单抗获批皮肤T细胞淋巴瘤两项新适应症</title><link>https://mp.weixin.qq.com/s/Qh0PMyaMgyX8OjuKNrhxoQ</link><description></description><content:encoded><![CDATA[武田注射用维布妥昔单抗获批皮肤T细胞淋巴瘤两项新适应症]]></content:encoded><pubDate>Fri, 16 Apr 2021 16:50:48 +0800</pubDate></item><item><title>读报告 涨知识 I IQVIA院内销售MAT202102增长率-6.7%</title><link>https://mp.weixin.qq.com/s/THENHUloPXLjLxcob4pr-Q</link><description></description><content:encoded><![CDATA[读报告 涨知识 I IQVIA院内销售MAT202102增长率-6.7%]]></content:encoded><pubDate>Thu, 15 Apr 2021 23:08:32 +0800</pubDate></item><item><title>PK指导重型血友病A儿童预防治疗-北京儿童医院单中心经验</title><link>https://mp.weixin.qq.com/s/8YIwSxfay3IRqpetrHIVGg</link><description></description><content:encoded><![CDATA[PK指导重型血友病A儿童预防治疗-北京儿童医院单中心经验]]></content:encoded><pubDate>Thu, 15 Apr 2021 23:08:32 +0800</pubDate></item><item><title>读报告 涨知识 I如何启动Medical Affairs的科学“核动力”</title><link>https://mp.weixin.qq.com/s/uRtVgt3YLoQCzXrTbbxMkg</link><description></description><content:encoded><![CDATA[读报告 涨知识 I如何启动Medical Affairs的科学“核动力”]]></content:encoded><pubDate>Wed, 14 Apr 2021 22:46:20 +0800</pubDate></item><item><title>【AACR2021】新一代ALK抑制剂NUV-655</title><link>https://mp.weixin.qq.com/s/bm9eoQykGC5YEbcPyrKWFw</link><description></description><content:encoded><![CDATA[【AACR2021】新一代ALK抑制剂NUV-655]]></content:encoded><pubDate>Wed, 14 Apr 2021 22:46:20 +0800</pubDate></item><item><title>MM课堂 | 姜华教授：2020 ASH新诊断多发性骨髓瘤治疗策略与进展</title><link>https://mp.weixin.qq.com/s/p5UTllRHUPyBFuVbkWm7rg</link><description></description><content:encoded><![CDATA[MM课堂 | 姜华教授：2020 ASH新诊断多发性骨髓瘤治疗策略与进展]]></content:encoded><pubDate>Wed, 14 Apr 2021 22:46:20 +0800</pubDate></item><item><title>【AACR2021】新一代ROS1抑制剂NUV-520</title><link>https://mp.weixin.qq.com/s/tnia15FPZX2gH2OLBdO3ww</link><description></description><content:encoded><![CDATA[【AACR2021】新一代ROS1抑制剂NUV-520]]></content:encoded><pubDate>Wed, 14 Apr 2021 22:46:20 +0800</pubDate></item><item><title>看报告 涨知识 I Pharma R&amp;D Annual Review 2021节选</title><link>https://mp.weixin.qq.com/s/0YC4f-Xko8cahdxOht0w5g</link><description></description><content:encoded><![CDATA[看报告 涨知识 I Pharma R&D Annual Review 2021节选]]></content:encoded><pubDate>Mon, 12 Apr 2021 22:55:48 +0800</pubDate></item><item><title>破除内卷，向外突围|2021CMAC参会杂感</title><link>https://mp.weixin.qq.com/s/r7aNOmAlhlwohwS3bT3_Qw</link><description></description><content:encoded><![CDATA[破除内卷，向外突围|2021CMAC参会杂感]]></content:encoded><pubDate>Mon, 12 Apr 2021 22:55:48 +0800</pubDate></item><item><title>CD30学院 | 白鸥教授——外周T细胞淋巴瘤免疫靶向治疗新进展</title><link>https://mp.weixin.qq.com/s/_maliIl_GrcG7y3UZLQo_Q</link><description></description><content:encoded><![CDATA[CD30学院 | 白鸥教授——外周T细胞淋巴瘤免疫靶向治疗新进展]]></content:encoded><pubDate>Mon, 12 Apr 2021 22:55:48 +0800</pubDate></item><item><title>【Cancer Discover】TAK-788用于EGFR外显子20插入突变经治晚期NSCLC的疗效和安全性</title><link>https://mp.weixin.qq.com/s/5Uous3ekV-5xK5bSZUCwzA</link><description></description><content:encoded><![CDATA[【Cancer Discover】TAK-788用于EGFR外显子20插入突变经治晚期NSCLC的疗效和安全性]]></content:encoded><pubDate>Sun, 11 Apr 2021 20:50:00 +0800</pubDate></item><item><title>攀岩模式环境下年会越来越有温度 | 第六届CMAC年会圆满落幕！</title><link>https://mp.weixin.qq.com/s/_Y4eH_Dk3Pat_LJZVgoZHg</link><description></description><content:encoded><![CDATA[攀岩模式环境下年会越来越有温度 | 第六届CMAC年会圆满落幕！]]></content:encoded><pubDate>Sun, 11 Apr 2021 20:50:00 +0800</pubDate></item><item><title>看新闻 涨知识 I keytruda肾细胞癌辅助临床研究达到主要研究终点DFS</title><link>https://mp.weixin.qq.com/s/kDV7Ncij1luX8NPOlxWeOw</link><description></description><content:encoded><![CDATA[看新闻 涨知识 I keytruda肾细胞癌辅助临床研究达到主要研究终点DFS]]></content:encoded><pubDate>Sun, 11 Apr 2021 16:37:24 +0800</pubDate></item><item><title>A+学院 | Daniel P·Hart教授：国外个体化治疗经验分享</title><link>https://mp.weixin.qq.com/s/arbjLlyk6TWUdRmGUlUIow</link><description></description><content:encoded><![CDATA[A+学院 | Daniel P·Hart教授：国外个体化治疗经验分享]]></content:encoded><pubDate>Sun, 11 Apr 2021 16:37:24 +0800</pubDate></item><item><title>内卷是黑话吗</title><link>https://mp.weixin.qq.com/s/-cDfobzIXfQ1JtxcHM_k_Q</link><description></description><content:encoded><![CDATA[内卷是黑话吗]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:54:38 +0800</pubDate></item><item><title>ASCO/OH(CCO)联合指南更新：携带驱动基因改变Ⅳ期非小细胞肺癌的治疗</title><link>https://mp.weixin.qq.com/s/LjKH8DXGKD4CXy6v2N95-g</link><description></description><content:encoded><![CDATA[ASCO/OH(CCO)联合指南更新：携带驱动基因改变Ⅳ期非小细胞肺癌的治疗]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:54:38 +0800</pubDate></item><item><title>MM课堂 | 刘延方教授：伊沙佐米治疗MM真实世界研究</title><link>https://mp.weixin.qq.com/s/UwmsWd-TvQ1V9uR3VDS5LQ</link><description></description><content:encoded><![CDATA[MM课堂 | 刘延方教授：伊沙佐米治疗MM真实世界研究]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:54:38 +0800</pubDate></item><item><title>看新闻 涨知识 I BMS宣布晚期食管鳞癌3期临床研究达到主要研究终点</title><link>https://mp.weixin.qq.com/s/uAQjF-YJP8fALRUNeJ7htg</link><description></description><content:encoded><![CDATA[看新闻 涨知识 I BMS宣布晚期食管鳞癌3期临床研究达到主要研究终点]]></content:encoded><pubDate>Thu, 08 Apr 2021 21:31:03 +0800</pubDate></item></channel></rss>